Abstract
Although cancer has classically been regarded as a genetic disease of uncontrolled cell growth, the importance of the tumor microenvironment (TME) [1, 2] is continuously emphasized by the accumulating evidence that cancer growth is not simply dependent on the cancer cells themselves [3, 4] but also dependent on angiogenesis [5–8], inflammation [9, 10], and the supporting roles of cancer-associated fibroblasts (CAFs) [11–13]. After the discovery that CAFs are able to remodel the tumor matrix within the TME and provide the nutrients and chemicals to promote cancer cell growth [14], many studies have aimed to uncover the cross talk between cancer cells and CAFs. Moreover, a new paradigm in cancer metabolism shows how cancer cells act like “metabolic parasites” to take up the high-energy metabolites, such as lactate, ketone bodies, free fatty acids, and glutamine from supporting cells, including CAFs and cancer-associated adipocytes (CAAs) [15, 16]. This chapter provides an overview of the metabolic coupling between CAFs and cancer cells to further define the therapeutic options to disrupt the CAF-cancer cell interactions.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Keywords
- Cancer-associated fibroblasts
- Cancer-associated adipocytes
- Tumor microenvironment
- Metabolism
- Metabolites
- Cancer therapy
-
Metabolic cross talk between CAFs and cancer can be a metabolic target for cancer therapy.
-
The reverse Warburg effects can be targeted via disruption of the “lactate shuttle” by MCT1/MCT 4 inhibitors.
-
Metformin can be used to inhibit glycolysis and block the function of CAFs, which promote cancer cell growth.
-
Blocking the glutamine uptake of cancer cells from CAFs is a strategy in targeting glutaminolysis.
-
Ketone bodies and ketosis in CAFs can be targeted for cancer treatment.
-
Fatty acid metabolism from cancer-associated adipocytes (CAAs) serves as a nutrient reservoir for cancer cell growth and is another target for cancer therapy.
1 Introduction
Although cancer has classically been regarded as a genetic disease of uncontrolled cell growth, the importance of the tumor microenvironment (TME) [1, 2] is continuously emphasized by the accumulating evidence that cancer growth is not simply dependent on the cancer cells themselves [3, 4] but also dependent on angiogenesis [5,6,7,8], inflammation [9, 10], and the supporting roles of cancer-associated fibroblasts (CAFs) [11,12,13]. After the discovery that CAFs are able to remodel the tumor matrix within the TME and provide the nutrients and chemicals to promote cancer cell growth [14], many studies have aimed to uncover the cross talk between cancer cells and CAFs. Moreover, a new paradigm in cancer metabolism shows how cancer cells act like “metabolic parasites” to take up the high-energy metabolites, such as lactate, ketone bodies, free fatty acids, and glutamine from supporting cells, including CAFs and cancer-associated adipocytes (CAAs) [15, 16]. This chapter provides an overview of the metabolic coupling between CAFs and cancer cells to further define the therapeutic options to disrupt the CAF-cancer cell interactions.
2 Overview of the Metabolism of CAFs in Solid Tumors
Pathological analysis shows that CAFs either are located in the tumor margin or infiltrate the tumor mass, indicating that CAFs and cancer cells are physically and functionally connected to each other [17, 18]. Of note, other than their locations, the physiological roles of CAFs depend on the existence of neighboring cancer cells [19], leading Madar et al. to propose a new concept: a “CAF state” instead of “cell type” [20].
Studying cancer metabolism is difficult due to the dynamic and rapid metabolic influx/efflux of heterogeneous cancer cells [2]. However, it is clear that the reprogramming of energy metabolism is one of the hallmarks of cancer [21]. Thus, researchers have sought to identify the metabolic vulnerabilities of cancer cells and exploit them for therapy [22, 23]. Cancer-friendly fibroblasts are the most abundant noncancerous cells in solid tumors, and they promote cancer cell growth and induce chemotherapy resistance [24]. Unfortunately, the underlying mechanism of how CAFs help in tumor cell growth remains unclear. However, recent progress in metabolic technologies, including stable isotope-resolved metabolomics, NMR-based metabolomics, and fluorescence-activated cell sorting [25,26,27,28,29], is deepening our insight into the metabolic cross talk between CAFs and cancer cells in the context of metabolic alterations. Using these advanced technologies, CAF-cancer cell interactions have been investigated in various types of cancers, including breast cancer [30], prostate cancer, ovarian cancer, lymphomas [31], non-small cell lung cancer, and head and neck cancers [24]. For instance, CAF produces and releases lactate to the TME, while cancer cells simultaneously utilize this lactate for mitochondrial oxidative phosphorylation (OXPHOS) in order to produce ATP efficiently and rapidly (Fig. 1). Interestingly, not only do CAFs produce these metabolites to help cancer cells grow, but cancer cells also release epidermal growth factor (EGF) to enhance the production and secretion of leptin by CAFs, which eventually leads to tumor progression [32]. Additionally, tumor cells express pro-inflammatory genes, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interleukin-1 (IL-1), so that normal fibroblasts can be guided by cancer cells to become pro-inflammatory CAFs [33] (Fig. 1).
Moreover, several studies have identified CAF gene expression profiles, including certain extracellular matrix (ECM) components and several matrix metalloproteases (MMP2, MMP11, and MMP14). These results suggest that ECM biosynthesis and remodeling is one of the critical features of the interplay between CAFs and cancer [34,35,36]. For instance, in ovarian and small cell lung cancers, many ECM genes remarkably elevate their expression levels in chemotherapy-treated cancer cells to induce chemoresistance [37, 38]. Additionally, CAFs bypass and help tumor cells resist anti-vascular endothelial growth factor (VEGF) treatment caused by angiogenesis inhibition by activating the platelet-derived growth factor C (PDGF-C) pathway [39], and stroma cells mediate RAF inhibitor resistance in BRAF-mutant melanoma through human growth hormone (HGH) secretion [40]. Even though gene expression profiles provide a method to predict the risks of metabolic coupling between cancer cells and CAFs, gene expression levels do not always correlate with metabolic changes. Therefore, measuring the metabolite levels in a sample could be a more accurate method to predict the risk of the aforementioned metabolic interplay.
3 Targeting the Metabolic Exchanges Between CAFs and Cancer Cells
3.1 Targeting the Reverse Warburg Effect via Disruption of the “Lactate Shuttle” by MCT1/MCT4 Inhibitors
Glycolysis, the process of converting glucose to pyruvate, is an essential metabolic pathway to produce energy in the form of ATP in cells. In the 1920s, Otto Warburg found that cancer cells preferably produce energy by converting glucose to lactic acid, even in aerobic conditions, to generate ATP rapidly. This is known as the Warburg effect [41, 42]. Interestingly, it was suggested that the reverse Warburg effect is the result of fibroblasts secreting lactate/pyruvate and epithelial cancer cells simultaneously taking up the energy-rich metabolites to utilize in the tricarboxylic acid (TCA) cycle and promote energy production for their growth [43]. In this hypothesis, cancer cells first guide the normal stromal cells to become CAFs, providing a tumor-friendly microenvironment to activate tumor growth. Next, lactate from CAFs is directly absorbed by the cancer cells as fuel for OXPHOS after the conversion of lactate to pyruvate [44]. Accordingly, the expression levels of glycolytic enzymes, such as lactate dehydrogenase and pyruvate kinase isozymes M2, and the lactate transporter, monocarboxylate transporter 4 (MCT4), are elevated in CAFs within breast and lung cancer tumors [24, 45]. Of note, lactate plays an important role in generating energy for the brain and the heart [46,47,48,49] and serves as an energy interplay shuttle between stromal cells and various types of cancer cells [45, 49, 50]. In this scenario, surrounding CAFs can communicate with cancer cells through direct cell-to-cell contact by releasing an exosome packaged with CAF-produced metabolites [51]. This coincides with neovascularization, inflammatory cell infiltration, and extensive remodeling of extracellular matrix in the TME [52]. Evidence supporting the “lactate shuttle” in human cancers [16, 53, 54] further shows that lactate can be directly transferred from CAFs to adjacent tumor cells under the premise that (1) CAFs overexpress the transmembrane monocarboxylate transporter 4 (MCT4) for lactate efflux from CAFs to cancer cells [53], (2) cancer cells overexpress monocarboxylate transporter 1 (MCT1) for lactate influx into cancer cells [45, 55], and (3) cancer cells finally utilize lactate as fuel for producing ATP via the TCA cycle [56,57,58]. Of note, MCT1 and MCT4, the main transporters of lactate, are key modulators of lactate homeostasis [59]. The elevated expression levels of genes involved in the lactate shuttle system, including high expression levels of MCT4, are associated with poor prognosis in the prostate, pancreas, and triple-negative breast cancers [59,60,61]. Consequently, accumulating evidence suggests that MCT1 and MCT4 transporters could be promising targets for cancer therapy.
Over the last decade, there has been significant progress in understanding the roles of the TME in tumorigenesis and the development of effective strategies for cancer therapy. In order to disrupt the metabolic bridge in CAF-cancer cell interactions through glycolysis and lactate metabolism inhibition, three potential strategies have been proposed. First, elevated expression of the lactate transporter MCT1 in cancer cells is a potential target for blocking cellular uptake of two types of mitochondrial fuels, ketone bodies and lactate [62]. MCT1 and MCT2 inhibitors can block the influx and efflux of lactate produced by either CAFs or cancer cells. Thus, due to the rapid accumulation of lactate and protons within cancer cells by inhibiting lactate influx/efflux, rapid acidification can occur in cancer cells and the TME, resulting in lactic acidosis [63,64,65]. For instance, alpha-cyano-4-hydroxy-cinnamic acid (ACCA), an MCT inhibitor, not only inhibits lactic acid efflux in glycolytic gliomas but also disrupts redox hemostasis and enhances radiosensitivity [66, 67]. AZD3965, an MCT1 inhibitor, is currently being tested in phase I clinical trial in solid tumors, including lymphoma, prostate cancer, and gastric cancer (NCT01791595) (Fig. 2). However, there are concerns over the alternative effects of MCT1 inhibitors, which include the blockage of lactate transport in muscles, gastrointestinal tract, and liver [68, 69].
3.2 Blocking the Function of CAFs by Metformin (Fig. 2)
Metformin, a drug that has been widely used for type 2 diabetes treatment, has found new applications as an anticancer drug for its glucose-targeting effects. Metformin activates the AMPK pathway and simultaneously inhibits cancer cell growth through the inhibition of glycolysis by facilitating the trafficking of glucose transporters 1 and 4 [70, 71]. Recent studies have also shown the therapeutic potential of metformin in blocking the function of CAFs [72]. In other words, metformin is sufficient to reverse the effects of CAFs on cancer cell growth [72], providing a rationale for why metformin is actively being tested in multiple clinical trials in solid tumors and lymphoma (NCTNCT00659568, NCT00881725, NCT00984490, and NCT00909506).
4 Targeting the Glutamine Uptake of Cancer Cells from CAFs
Glutamine addiction is a physiological phenomenon where cancer cells rely on the presence of exogenous glutamine to be used as a fuel for the TCA cycle and as a nitrogen donor for nucleotide and amino acid synthesis [73,74,75,76]. It was recently revealed that CAFs produce and release glutamine, while cancer cells take up and utilize this glutamine from the TME as an alternative carbon and nitrogen source [51, 77]. This explains why glutamine transporters, alanine, serine, cysteine preferring transporter 2 (ASCT2), and solute carrier family 38 member 5 (SLC38A5) are usually overexpressed in breast and prostate cancers [78,79,80]. Of note, ASCT2 mediates the uptake of glutamine, an essential amino acid in triple-negative basal-like breast cancer [80]. And ASCT2 inhibitors, such as benzylserine and L-γ-glutamyl-p-nitroanilide, have been shown to inhibit glutamine uptake and cell growth in melanoma and endometrial carcinoma [81,82,83] (Fig. 2). Additionally, FDA-approved tamoxifen and raloxifene also suppress estrogen receptor-negative breast cancer growth by inhibiting glutamine uptake [84].
5 Targeting Ketone Bodies and Ketosis in CAFs
Ketone bodies such as acetoacetate, β-hydroxybutyrate (βOHB), and acetone are produced through fatty acid metabolism in the liver [85]. Liver hepatocytes convert fatty acids into ketone bodies and release them into the bloodstream, especially under starvation conditions or after excessive exercises. Consequently, through ketolysis, a process of the conversion of ketone bodies into acetyl-CoA, they feed into the TCA cycle or OXPHOS to generate ATP [86]. Recent studies have shown that CAFs secrete ketone bodies and cancer cells utilize them as energy sources [77, 85, 87]. Furthermore, Bonuccelli et al. observed that ketone bodies, especially βOHB, serve as a more powerful energy source for cancer cell growth in comparison to lactate [88]. Genes associated with ketolysis and ketogenesis in CAFs, including 3-hydroxybutyrate dehydrogenase 1 (BDH1) and 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), were overexpressed [89, 90]. Specifically, BDH1 catalyzes the conversion of acetoacetate to βOHB. HMGCS2, a member of the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase family, generates HMG-CoA [86, 91]. In contrast to the gene expression profile of the surrounding epithelial cells, cancer cells themselves have upregulated gene expressions associated with ketone reutilization (acetyl-CoA acetyltransferase, ACAT1) and mitochondrial biogenesis (heat-shock protein 60, HSP60) [89]. Moreover, ketone bodies can be a source of lactate and pyruvate because acetone—an end product of ketosis—can be metabolized to lactate and pyruvate [92, 93]. Taken together, this suggests that the ketone bodies produced by CAFs can serve as an energy fuel for tumor growth and have further implications as a potential therapeutic target for cancer therapy. Furthermore, ketone bodies, including βOHB, are transported by the monocarboxylate transporters (MCT1 and MCT2), which also transport them across the blood-brain barrier [91, 94]. Accordingly, treatments targeting MCT1 and MCT2 are currently being tested in phase I clinical trials in solid tumor cancers (NCT01791595) [95]. Thus, the MCT1 and MCT2 inhibitors may effectively block the transport of lactate and ketone bodies, both generated by CAFs (Fig. 2).
6 Targeting Fatty Acid, a Nutrient Reservoir for Cancer Cell Growth, from Cancer-Associated Adipocytes (CAAs)
Cancer-associated adipocytes (CAAs) play an important tumorigenic role in fatty acid metabolism in the TME. For instance, omental adipocytes promote the migration and invasion of ovarian cancer cells to the omentum [96, 97]. It is known that omental adipocytes generate free fatty acids (FFAs) that are further transferred to cancer cells to generate ATP via β-oxidation [98] (Fig. 1). Therefore, in order to utilize FFAs, a subset of cancer cells overexpress the fatty acid-binding protein 4 (FABP4), which plays a key role in fatty acid transport for ovarian and breast cancer metastasis [15, 96, 99] (Fig. 1). It has been shown that a FABP4 inhibitor, which binds long-chain fatty acids, reduces metastasis of prostate cancer and regulates fatty acid production in ovarian and prostate cancers [96, 100] (Fig. 2). Because adipocytes are a major component of the TME in breast and ovarian cancers, it may be a rationale for FABP4’s effectiveness in those cancers [96, 101]. Accumulation of fatty acids in the TME could serve as a nutrient reservoir for cancer cell growth during nutrient deprivation. Taken together, stromal catabolites, such as free fatty acids, promote tumor growth, and act as chemoattractants to metastasizing cancer cells in the omentum.
7 Conclusion
The TME is comprised of cancer cells, CAFs, immune cells, adipocytes, and other supporting cells. Of these, CAFs are one of the key regulators of tumorigenesis. Within the TME of solid tumors, heterogeneous cancer cells and CAFs interact by transferring their metabolites, including amino acids, fatty acids, ketone bodies, cytokines, and growth factors, which reciprocally facilitate the growth of cancer cells. Moreover, CAFs provide not only a structural matrix for providing a tumor-friendly microenvironment to cancer cells but also nutrients for cancer cells. As such, the metabolic interplay between CAFs and cancer cells is considered as an area of vulnerability among cancer cells given that (1) cancer cells release HGH and induce pro-inflammatory gene expression in CAFs, (2) CAFs produce and release high-energy metabolites to the TME, and (3) cancer cells take up those metabolites to produce energy for cancer growth. Therefore, it is widely accepted that CAF-mediated metabolism plays a key role in tumorigenesis and that targeting the metabolic cross talk between cancer cells and CAFs can serve as a potential target for cancer therapy. Consequently, researchers have made continuous efforts to exploit areas of metabolic vulnerability by targeting (1) glycolysis and lactate metabolism, (2) glutaminolysis, (3) ketone bodies and ketosis, and (4) fatty acid metabolism.
Abbreviations
- ACAT1:
-
Acetyl-CoA acetyltransferase
- ACC:
-
Acetyl-CoA carboxylase
- ACCA:
-
Alpha-cyano-4-hydroxycinnamic acid
- ASCT2:
-
Alanine, serine, cysteine-preferring transporter 2
- BDH1:
-
3-Hydroxybutyrate dehydrogenase 1
- CAAs:
-
Cancer-associated adipocytes
- CAFs:
-
Cancer-associated fibroblasts
- ECM:
-
Extracellular matrix
- EGF:
-
Epidermal growth factor
- HGH:
-
Human growth hormone
- HMG-CoA:
-
3-Hydroxy-3-methylglutaryl-CoA
- HMGCS2:
-
3-Hydroxy-3-methylglutaryl-CoA synthase 2
- HSP60:
-
Heat-shock protein 60
- IL-1:
-
Interleukin-1
- MCT1:
-
Monocarboxylate transporter 1
- MCT4:
-
Monocarboxylate transporter 4
- MMP:
-
Matrix metalloprotease
- NF-κB:
-
Nuclear factor kappa-light chain-enhancer of activated B cells
- OXPHOS:
-
Oxidative phosphorylation
- SLC38A5:
-
Solute carrier family 38 member 5
- TCA:
-
Tricarboxylic acid
- TME:
-
Tumor microenvironment
- VEGF:
-
Vascular endothelial growth factor
- βOHB:
-
β-Hydroxybutyrate
References
Antonio, M. J., Zhang, C., & Le, A. (2021). Different tumor microenvironments lead to different metabolic phenotypes. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_10.
Nabi, K., & Le, A. (2021). The intratumoral heterogeneity of cancer metabolism. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_11.
Bissell, M. J., & Radisky, D. (2001). Putting tumours in context. Nature Reviews. Cancer, 1(1), 46–54.
Tlsty, T. D., & Coussens, L. M. (2006). Tumor stroma and regulation of cancer development. Annual Review of Pathology, 1, 119–150.
Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine, 285(21), 1182–1186.
O’Reilly, M. S., et al. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88(2), 277–285.
Kalluri, R. (2003). Basement membranes: Structure, assembly and role in tumour angiogenesis. Nature Reviews. Cancer, 3(6), 422–433.
Kim, K. J., et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362(6423), 841–844.
Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867.
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 7(5), 411–423.
Tlsty, T. D., & Hein, P. W. (2001). Know thy neighbor: Stromal cells can contribute oncogenic signals. Current Opinion in Genetics & Development, 11(1), 54–59.
Elenbaas, B., & Weinberg, R. A. (2001). Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Experimental Cell Research, 264(1), 169–184.
Sazeides, C., & Le, A. (2021). Metabolic relationship between cancer-associated fibroblasts and cancer cells. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_14.
Calvo, F., et al. (2015). Cdc42EP3/BORG2 and septin network enables mechano-transduction and the emergence of cancer-associated fibroblasts. Cell Reports, 13(12), 2699–2714.
Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P. (2012). Power surge: Supporting cells “fuel” cancer cell mitochondria. Cell Metabolism, 15(1), 4–5.
Martinez-Outschoorn, U. E., et al. (2011). Energy transfer in “parasitic” cancer metabolism: Mitochondria are the powerhouse and Achilles’ heel of tumor cells. Cell Cycle, 10(24), 4208–4216.
Kilvaer, T. K., et al. (2015). Cancer associated fibroblasts in stage I-IIIA NSCLC: Prognostic impact and their correlations with tumor molecular markers. PLoS One, 10(8), e0134965.
Ha, S. Y., et al. (2014). The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLoS One, 9(6), e99955.
Cheteh, E. H., et al. (2017). Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death & Disease, 8(6), e2848.
Madar, S., Goldstein, I., & Rotter, V. (2013). ‘Cancer associated fibroblasts’—more than meets the eye. Trends in Molecular Medicine, 19(8), 447–453.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
Dang, C. V., et al. (2011). Therapeutic targeting of cancer cell metabolism. Journal of Molecular Medicine (Berlin), 89(3), 205–212.
Hirschey, M. D., et al. (2015). Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 35(Suppl), S129–S150.
Martinez-Outschoorn, U. E., Lisanti, M. P., & Sotgia, F. (2014). Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Seminars in Cancer Biology, 25, 47–60.
Hoang, G., Udupa, S., & Le, A. (2019). Application of metabolomics technologies toward cancer prognosis and therapy. International Review of Cell and Molecular Biology, 347, 191–223.
Bruntz, R. C., et al. (2017). Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM). The Journal of Biological Chemistry, 292(28), 11601–11609.
Fan, T. W., et al. (2009). Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Molecular Cancer, 8, 41.
Elgogary, A., et al. (2016). Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(36), E5328–E5336.
Lane, A. N., & Fan, T. W. (2017). NMR-based stable isotope resolved metabolomics in systems biochemistry. Archives of Biochemistry and Biophysics, 628, 123–131.
Tan, J., & Le, A. (2021). The heterogeneity of breast cancer metabolism. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_6.
Kirsch, B. J., et al. (2021). Non-Hodgkin lymphoma metabolism. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_7.
Barone, I., et al. (2012). Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Research, 72(6), 1416–1427.
Erez, N., et al. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135–147.
Casey, T., et al. (2009). Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Research and Treatment, 114(1), 47–62.
Ma, X. J., et al. (2009). Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Research, 11(1), R7.
Finak, G., et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine, 14(5), 518–527.
Sherman-Baust, C. A., et al. (2003). Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell, 3(4), 377–386.
Hodkinson, P. S., Mackinnon, A. C., & Sethi, T. (2007). Extracellular matrix regulation of drug resistance in small-cell lung cancer. International Journal of Radiation Biology, 83(11–12), 733–741.
Crawford, Y., et al. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell, 15(1), 21–34.
Straussman, R., et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487(7408), 500–504.
Bose, S., Zhang, C., & Le, A. (2021). Glucose metabolism in cancer: The Warburg effect and beyond. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_1.
Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.
Pavlides, S., et al. (2009). The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle, 8(23), 3984–4001.
Lee, M., & Yoon, J. H. (2015). Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World Journal of Biological Chemistry, 6(3), 148–161.
Faubert, B., et al. (2017). Lactate metabolism in human lung tumors. Cell, 171(2), 358–371. e9.
van Hall, G., et al. (2009). Blood lactate is an important energy source for the human brain. Journal of Cerebral Blood Flow and Metabolism, 29(6), 1121–1129.
Medina, J. M., & Tabernero, A. (2005). Lactate utilization by brain cells and its role in CNS development. Journal of Neuroscience Research, 79(1–2), 2–10.
Bartelds, B., et al. (1999). Myocardial lactate metabolism in fetal and newborn lambs. Circulation, 99(14), 1892–1897.
Fujiwara, S., et al. (2015). Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Experimental Hematology & Oncology, 4, 12.
Hirschhaeuser, F., Sattler, U. G., & Mueller-Klieser, W. (2011). Lactate: A metabolic key player in cancer. Cancer Research, 71(22), 6921–6925.
Zhao, H., et al. (2016). Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. eLife, 5, e10250.
Ronnov-Jessen, L., Petersen, O. W., & Bissell, M. J. (1996). Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. Physiological Reviews, 76(1), 69–125.
Whitaker-Menezes, D., et al. (2011). Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle, 10(11), 1772–1783.
Rattigan, Y. I., et al. (2012). Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Experimental Cell Research, 318(4), 326–335.
Hong, C. S., et al. (2016). MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Reports, 14(7), 1590–1601.
Gladden, L. B. (2004). Lactate metabolism: A new paradigm for the third millennium. The Journal of Physiology, 558(Pt 1), 5–30.
Draoui, N., & Feron, O. (2011). Lactate shuttles at a glance: From physiological paradigms to anti-cancer treatments. Disease Models & Mechanisms, 4(6), 727–732.
Sonveaux, P., et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation, 118(12), 3930–3942.
Baek, G., et al. (2014). MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Reports, 9(6), 2233–2249.
Pertega-Gomes, N., et al. (2014). A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer, 14, 352.
Witkiewicz, A. K., et al. (2012). Using the “reverse Warburg effect” to identify high-risk breast cancer patients: Stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle, 11(6), 1108–1117.
Lamb, R., et al. (2014). Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget, 5(22), 11029–11037.
Wu, H., et al. (2012). Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. The Journal of Pathology, 227(2), 189–199.
Xie, J., et al. (2014). Beyond Warburg effect--dual metabolic nature of cancer cells. Scientific Reports, 4, 4927.
Romero-Garcia, S., et al. (2016). Lactate contribution to the tumor microenvironment: Mechanisms, effects on immune cells and therapeutic relevance. Frontiers in Immunology, 7, 52.
Colen, C. B., et al. (2011). Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: An in vivo study. Neoplasia, 13(7), 620–632.
Colen, C. B., et al. (2006). Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: An in vitro study. Neurosurgery, 59(6), 1313–1323. discussion 1323-4.
Ovens, M. J., et al. (2010). AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. The Biochemical Journal, 425(3), 523–530.
Perez-Escuredo, J., et al. (2016). Monocarboxylate transporters in the brain and in cancer. Biochimica et Biophysica Acta, 1863(10), 2481–2497.
Ben Sahra, I., et al. (2010). Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics, 9(5), 1092–1099.
Kozka, I. J., et al. (1995). The effects of insulin on the level and activity of the GLUT4 present in human adipose cells. Diabetologia, 38(6), 661–666.
Martinez-Outschoorn, U. E., et al. (2010). Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle, 9(16), 3256–3276.
Li, T., Copeland, C., & Le, A. (2021). Glutamine metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_2.
Le, A., et al. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metabolism, 15(1), 110–121.
Wise, D. R., & Thompson, C. B. (2010). Glutamine addiction: A new therapeutic target in cancer. Trends in Biochemical Sciences, 35(8), 427–433.
Romero, I. L., et al. (2015). Molecular pathways: Trafficking of metabolic resources in the tumor microenvironment. Clinical Cancer Research, 21(4), 680–686.
Pavlides, S., et al. (2010). The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle, 9(17), 3485–3505.
Wang, Q., et al. (2015). Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. The Journal of Pathology, 236(3), 278–289.
Gupta, S., Roy, A., & Dwarakanath, B. S. (2017). Metabolic cooperation and competition in the tumor microenvironment: Implications for therapy. Frontiers in Oncology, 7, 68.
van Geldermalsen, M., et al. (2016). ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene, 35(24), 3201–3208.
Wang, Q., et al. (2014). Targeting glutamine transport to suppress melanoma cell growth. International Journal of Cancer, 135(5), 1060–1071.
Esslinger, C. S., Cybulski, K. A., & Rhoderick, J. F. (2005). Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorganic & Medicinal Chemistry, 13(4), 1111–1118.
Marshall, A. D., et al. (2017). ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. Oncogene, 6(7), e367.
Todorova, V. K., et al. (2011). Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemotherapy and Pharmacology, 67(2), 285–291.
Wu, D., Zhuo, L., & Wang, X. (2017). Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors. Seminars in Cell & Developmental Biology, 64, 125–131.
Grabacka, M., et al. (2016). Regulation of ketone body metabolism and the role of PPARalpha. International Journal of Molecular Sciences, 17, 12.
Fiaschi, T., et al. (2012). Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Research, 72(19), 5130–5140.
Bonuccelli, G., et al. (2010). Ketones and lactate “fuel” tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle, 9(17), 3506–3514.
Martinez-Outschoorn, U. E., et al. (2012). Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle, 11(21), 3956–3963.
Saraon, P., et al. (2013). Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Molecular & Cellular Proteomics, 12(6), 1589–1601.
Newman, J. C., & Verdin, E. (2014). Ketone bodies as signaling metabolites. Trends in Endocrinology and Metabolism, 25(1), 42–52.
Glew, R. H. (2010). You can get there from here: Acetone, anionic ketones and even-carbon fatty acids can provide substrates for gluconeogenesis. Nigerian Journal of Physiological Sciences, 25(1), 2–4.
Miller, O. N., & Bazzano, G. (1965). Propanediol metabolism and its relation to lactic acid metabolism. Annals of the New York Academy of Sciences, 119(3), 957–973.
Pellerin, L., et al. (2005). Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. Journal of Neuroscience Research, 79(1-2), 55–64.
Halford, S., et al. (2017). A first-in-human first-inclass (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. Journal of Clinical Oncology, 35(15_Suppl), 2516.
Nieman, K. M., et al. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine, 17(11), 1498–1503.
Vinokurov, V. L., & Kolosov, A. E. (1980). Ovarian cancer metastasis to the greater omentum. Voprosy Onkologii, 26(2), 30–34.
Park, J. K., et al. (2021). The heterogeneity of lipid metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_3.
Guaita-Esteruelas, S., et al. (2017). Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. Molecular Carcinogenesis, 56(1), 208–217.
Uehara, H., et al. (2014). Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. International Journal of Cancer, 135(11), 2558–2568.
Dirat, B., et al. (2011). Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Research, 71(7), 2455–2465.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2021 The Author(s)
About this chapter
Cite this chapter
Jung, J.G., Le, A. (2021). Targeting Metabolic Cross Talk Between Cancer Cells and Cancer-Associated Fibroblasts. In: Le, A. (eds) The Heterogeneity of Cancer Metabolism. Advances in Experimental Medicine and Biology, vol 1311. Springer, Cham. https://doi.org/10.1007/978-3-030-65768-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-65768-0_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-65767-3
Online ISBN: 978-3-030-65768-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)